1436 related articles for article (PubMed ID: 37086735)
1. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
3. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
[TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
5. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
6. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
[TBL] [Abstract][Full Text] [Related]
7. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
[TBL] [Abstract][Full Text] [Related]
11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
12. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
[TBL] [Abstract][Full Text] [Related]
13. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
McMenamin ME; Nealon J; Lin Y; Wong JY; Cheung JK; Lau EHY; Wu P; Leung GM; Cowling BJ
Lancet Infect Dis; 2022 Oct; 22(10):1435-1443. PubMed ID: 35850128
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
[TBL] [Abstract][Full Text] [Related]
16. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
[TBL] [Abstract][Full Text] [Related]
19. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study.
Wan EYF; Mok AHY; Yan VKC; Chan CIY; Wang B; Lai FTT; Chui CSL; Li X; Wong CKH; Lau CS; Wong ICK; Chan EWY
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36250571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
